Genetic deletion and pharmacological inhibition of PI3K γ reduces neutrophilic airway inflammation and lung damage in mice with cystic fibrosis-like lung disease

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Galluzzo, Maria ^a   Ciraolo, Elisa ^b   Lucattelli, Monica ^c   Hoxha, Eriola ^b   Ulrich, Martina ^d   Campa, Carlo Cosimo ^b   Lungarella, Giuseppe ^c   Doring, Gerd ^d   Zhou Suckow, Zhe ^e   Mall, Marcus ^e   Hirsch, Emilio ^b   De Rose, Virginia ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; EPITHELIAL SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL BETA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CG PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; ENZYME INHIBITION; GENE DELETION; GENE OVEREXPRESSION; HISTOLOGY; IN VIVO STUDY; INFLAMMATORY CELL; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; MORPHOMETRICS; MORTALITY; MOUSE; NEUTROPHIL COUNT; NEUTROPHILIA; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; SURVIVAL RATE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; COMPLICATION; GENETICS; INFLAMMATION; LUNG; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS;

ANIMALS; CLASS IB PHOSPHATIDYLINOSITOL 3-KINASE; CYSTIC FIBROSIS; EPITHELIAL SODIUM CHANNELS; GENE DELETION; INFLAMMATION; LUNG; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEUTROPHIL INFILTRATION;

EID: 84936792007     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/545417     Document Type: Article

References (54)

1. F. Ratjen and G. Döring, "Cystic fibrosis" The Lancet, vol. 361, no. 9358, pp. 681-689, 2003.
2. B. P.O'SullivanandS.D. Freedman, "Cysticfibrosis"TheLancet, vol. 373, no. 9678, pp. 1891-1904, 2009.
3. M. A. Mall and D. Hartl, "CFTR: cystic fibrosis and beyond" European Respiratory Journal, vol. 44, no. 4, pp. 1042-1054, 2014.
4. P. D. Sly, C. L. Gangell, L. Chen et al., "Risk factors for bronchiectasis in children with cystic fibrosis"TheNewEngland Journal of Medicine, vol. 368, no. 21, pp. 1963-1970, 2013.
5. S. D. Sagel, B. D. Wagner, M. M. Anthony, P. Emmett, and E. T. Zemanick, "Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis" American Journal of Respiratory and Critical Care Medicine, vol. 186, no. 9, pp. 857-865, 2012.
6. S. Gehrig, J. Duerr, M. Weitnauer et al., "Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosislike lung disease" American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 9, pp. 1082-1092, 2014.
7. V. de Rose, "Mechanisms and markers of airway inflammation in cystic fibrosis" European Respiratory Journal, vol. 19, no. 2, pp. 333-340, 2002.
8. J. F. Chmiel and M. W. Konstan, "Inflammation and antiinflammatory therapies for cystic fibrosis" Clinics in Chest Medicine, vol. 28, no. 2, pp. 331-346, 2007.
9. M. Cohen-Cymberknoh, E. Kerem, T. Ferkol, and A. Elizur, "Airway inflammation in cystic fibrosis: molecularmechanisms and clinical implications" Thorax, vol. 68, no. 12, pp. 1157-1162, 2013.
10. W. A. Prescott Jr. and G. E. Johnson, "Anti-inflammatory therapies for cystic fibrosis: past, present, and future" Pharmacotherapy, vol. 25, no. 4, pp. 555-573, 2005.
11. E. Hirsch, V. L. Katanaev, C. Garlanda et al., "Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation" Science, vol. 287, no. 5455, pp. 1049-1052, 2000.
12. E. Hirsch, E. Ciraolo, A. Ghigo, andC. Costa, "Taming thePI3K team to hold inflammation and cancer at bay" Pharmacology andTherapeutics, vol. 118, no. 2, pp. 192-205, 2008.
13. A. Ghigo, F. Damilano, L. Braccini, and E. Hirsch, "PI3K inhibition in inflammation: toward tailored therapies for specific diseases" BioEssays, vol. 32, no. 3, pp. 185-196, 2010.
14. A. Ghigo, F. Morello, A. Perino, and E. Hirsch, "Phosphoinositide 3-kinases in health and disease" in Phosphoinositides I: Enzymes of Synthesis andDegradation, vol. 58 of Subcellular Biochemistry, pp. 183-213, Springer, Dordrecht, The Netherlands, 2012.
15. M. Mall, B. R. Grubb, J. R. Harkema, W. K. O'Neal, and R. C. Boucher, "Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice" Nature Medicine, vol. 10, no. 5, pp. 487-493, 2004.
16. Z. Zhou, J. Duerr, B. Johannesson et al., "The ENaCoverexpressing mouse as a model of cystic fibrosis lung disease" Journal of Cystic Fibrosis, vol. 10, supplement 2, pp. S172-S182, 2011.
17. M. O. Wielpütz, M. Eichinger, Z. Zhou et al., "In vivo monitoring of cystic fibrosis-like lung disease in mice by volumetric computed tomography" European Respiratory Journal, vol. 38, no. 5, pp. 1060-1070, 2011.
18. B. Johannesson, S. Hirtz, J. Schatterny, C. Schultz, and M. A. Mall, "CFTR regulates early pathogenesis of chronic obstructive lung disease in enac-overexpressing mice" PLoS ONE, vol. 7, no. 8, Article ID e44059, 2012.
19. M. A. Mall, J. R. Harkema, J. B. Trojanek et al., "Development of chronic bronchitis and emphysema in beta-epithelial Na+ channel-overexpressing mice" The American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 7, pp. 730-742, 2008.
20. W. Scherle, "A simple method for volumetry of organs in quantitative stereology" Mikroskopie, vol. 26, no. 1, pp. 57-60, 1970.
21. W. M. Thurlbeck, "Measurement of pulmonary emphysema." The American Review of Respiratory Disease, vol. 95, no. 5, pp. 752-764, 1967.
22. W. M. Thurlbeck, "Theinternal surface area of nonemphysematous lungs" American Review of Respiratory Disease, vol. 95, no. 5, pp. 765-773, 1967.
23. L. Atzori, M. Lucattelli, C. J. Scotton et al., "Absence of proteinase-Activated receptor-1 signaling in mice confers protection from fMLP-induced goblet cell metaplasia" The American Journal of Respiratory Cell and Molecular Biology, vol. 41, no. 6, pp. 680-687, 2009.
24. A. Livraghi, B. R. Grubb, E. J. Hudson et al., "Airway and lung pathology due to mucosal surface dehydration in-epithelial Na+ channel-overexpressing mice: role of TNF-And IL-4R signaling, influence of neonatal development, and limited efficacy of glucocorticoid treatment" Journal of Immunology, vol. 182, no. 7, pp. 4357-4367, 2009.
25. J. A. Voynow, B. M. Fischer, D. E. Malarkey et al., "Neutrophil elastase induces mucus cell metaplasia in mouse lung" The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 287, no. 6, pp. L1293-L1302, 2004.
26. J.A. Voynow, L. R. Young, Y. Wang, T. Horger, M. C. Rose, and B. M. Fischer, "Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells" The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 276, no. 5, pp. L835-L843, 1999.
27. C. H. Goss and J. L. Burns, "Exacerbations in cystic fibrosis1: epidemiology and pathogenesis" Thorax, vol. 62, no. 4, pp. 360-367, 2007.
28. M. W. Konstan, W. J. Morgan, S. M. Butler et al., "Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis" Journal of Pediatrics, vol. 151, no. 2, pp. 134.e1-139.e1, 2007.
29. M.W. Konstan, P. J. Byard, C. L. Hoppel, and P. B. Davis, "Effect of high-dose ibuprofen in patients with cystic fibrosis" New England Journal of Medicine, vol. 332, no. 13, pp. 848-854, 1995.
30. M. W. Konstan, "Ibuprofen therapy for cystic fibrosis lung disease: revisited" Current Opinion in PulmonaryMedicine, vol. 14, no. 6, pp. 567-573, 2008.
31. M. W. Konstan, G. Döring, S. L. Heltshe et al., "A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis" Journal of Cystic Fibrosis, vol. 13, no. 2, pp. 148-155, 2014.
32. M. Camps, T. Ruckle, H. Ji, and V. Ardissone, "Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis" Nature Medicine, vol. 11, pp. 936-943, 2005.
33. M.A. Mall, S. Y. Graeber, M. Stahl, and Z. Zhou-Suckow, "Early cystic fibrosis lung disease: role of airway surface dehydration and lessons from preventive rehydration therapies in mice" International Journal of Biochemistry and Cell Biology, vol. 52, pp. 174-179, 2014.
34. M. A. Mall, B. Button, B. Johannesson et al., "Airway surface liquid volume regulation determines different airway phenotypes in liddle compared with betaENaC-overexpressing mice" The Journal of Biological Chemistry, vol. 285, no. 35, pp. 26945-26955, 2010.
35. J. B. Trojanek, A. Cobos-Correa, S. Diemer et al., "Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema" The American Journal of Respiratory Cell and Molecular Biology, vol. 51, no. 5, pp. 709-720, 2014.
36. S. D. Shapiro, N. M. Goldstein, A. M. Houghton, D. K. Kobayashi, D. Kelley, and A. Belaaouaj, "Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice" American Journal of Pathology, vol. 163, no. 6, pp. 2329-2335, 2003.
37. A. Churg and J. L. Wright, "Proteases and emphysema" Current Opinion in PulmonaryMedicine, vol. 11, no. 2, pp. 153-159, 2005.
38. R. D. Hautamaki, D. K. Kobayashi, R. M. Senior, and S. D. Shapiro, "Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice" Science, vol. 277, no. 5334, pp. 2002-2004, 1997.
39. M. Fujita, J. M. Shannon, C. G. Irvin et al., "Overexpression of tumor necrosis factor-Alpha produces an increase in lung volumes and pulmonary hypertension" The American Journal of Physiology-Lung Cellular andMolecular Physiology, vol. 280, no. 1, pp. L39-L49, 2001.
40. T. Zheng, Z. Zhu, Z. Wang et al., "Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase-And cathepsindependent emphysema" Journal of Clinical Investigation, vol. 106, no. 9, pp. 1081-1093, 2000.
41. J. A. Voynow, B.M. Fischer, and S. Zheng, "Proteases and cystic fibrosis" International Journal of Biochemistry and Cell Biology, vol. 40, no. 6-7, pp. 1238-1245, 2008.
42. C. A. Owen, "Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease" International Journal of Chronic Obstructive Pulmonary Disease, vol. 3, no. 2, pp. 253-268, 2008.
43. C. T. N. Pham, "Neutrophil serine proteases: specific regulators of inflammation" Nature Reviews Immunology, vol. 6, no. 7, pp. 541-550, 2006.
44. W. L. Lee and G. P. Downey, "Leukocyte elastase: physiological functions and role in acute lung injury" American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 5, pp. 896-904, 2001.
45. J. V. Fahy and B. F. Dickey, "Airway mucus function and dysfunction"The New England Journal ofMedicine, vol. 363, no. 23, pp. 2233-2247, 2010.
46. R. L. Gibson, J. L. Burns, and B.W. Ramsey, "Pathophysiology and management of pulmonary infections in cystic fibrosis" American Journal of Respiratory and Critical CareMedicine, vol. 168, no. 8, pp. 918-951, 2003.
47. C. C. Taggart, C. M. Greene, T. P. Carroll, S. J. O'Neill, and N. G. McElvaney, "Elastolytic proteases: inflammation resolution and dysregulation in chronic infective lung disease" American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 10, pp. 1070-1076, 2005.
48. J. D. Venable, M. K. Ameriks, J. M. Blevitt, R. L. Thurmond, and W.-P. Fung-Leung, "Phosphoinositide 3-kinase gamma(PI3K) inhibitors for the treatment of inflammation and autoimmune disease" Recent Patents on Inflammation and Allergy Drug Discovery, vol. 4, no. 1, pp. 1-15, 2010.
49. J. G. Foster, M. D. Blunt, E. Carter, and S. G. Ward, "Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies" Pharmacological Reviews, vol. 64, no. 4, pp. 1027-1054, 2012.
50. B. Markman, J. J. Tao, and M. Scaltriti, "PI3K pathway inhibitors: better not left alone" Current PharmaceuticalDesign, vol. 19, no. 5, pp. 895-906, 2013.
51. T. D. Cushing, D. P. Metz, D. A. Whittington, and L. R. McGee, "PI3Kdelta and PI3Kgamma as targets for autoimmune and inflammatory diseases" Journal ofMedicinal Chemistry, vol. 55, no. 20, pp. 8559-8581, 2012.
52. A. Fougerat, S. Gayral, P. Gourdy et al., "Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes" Circulation, vol. 117, no. 10, pp. 1310-1317, 2008.
53. A. Ghigo, A. Perino, H. Mehel et al., "Phosphoinositide 3-kinase gamma protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases" Circulation, vol. 126, no. 17, pp. 2073-2083, 2012.
54. U.A. Maus, M. Backi, C. Winter et al., "Importance of phosphoinositide 3-kinase in the host defense against pneumococcal infection" American Journal of Respiratory and Critical Care Medicine, vol. 175, no. 9, pp. 958-966, 2007.